Retrophin Inc (RTRX) Expected to Post Quarterly Sales of $44.21 Million

Wall Street analysts expect that Retrophin Inc (NASDAQ:RTRX) will report sales of $44.21 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Retrophin’s earnings, with the highest sales estimate coming in at $44.39 million and the lowest estimate coming in at $44.02 million. Retrophin reported sales of $42.18 million in the same quarter last year, which suggests a positive year over year growth rate of 4.8%. The business is scheduled to report its next quarterly earnings results on Tuesday, February 26th.

According to Zacks, analysts expect that Retrophin will report full year sales of $164.28 million for the current year, with estimates ranging from $163.50 million to $164.86 million. For the next financial year, analysts expect that the business will post sales of $176.98 million, with estimates ranging from $172.63 million to $184.81 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Retrophin.

Several research firms have recently issued reports on RTRX. Jefferies Financial Group began coverage on Retrophin in a research note on Tuesday, October 30th. They issued a “buy” rating and a $44.00 price objective for the company. BidaskClub lowered Retrophin from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. ValuEngine lowered Retrophin from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 17th. Zacks Investment Research lowered Retrophin from a “hold” rating to a “strong sell” rating in a research note on Thursday, November 8th. Finally, Nomura began coverage on Retrophin in a research note on Monday, November 19th. They issued a “buy” rating and a $57.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $48.00.

In related news, SVP Elizabeth E. Reed sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 14th. The stock was sold at an average price of $23.73, for a total transaction of $59,325.00. Following the completion of the sale, the senior vice president now directly owns 20,627 shares of the company’s stock, valued at approximately $489,478.71. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Steve Aselage sold 12,376 shares of the firm’s stock in a transaction that occurred on Friday, December 21st. The stock was sold at an average price of $21.88, for a total value of $270,786.88. Following the sale, the chief executive officer now directly owns 265,960 shares of the company’s stock, valued at $5,819,204.80. The disclosure for this sale can be found here. Insiders sold a total of 68,611 shares of company stock valued at $1,583,635 over the last ninety days. Corporate insiders own 3.67% of the company’s stock.

Several hedge funds have recently modified their holdings of RTRX. The Manufacturers Life Insurance Company lifted its stake in shares of Retrophin by 21.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,845,403 shares of the biopharmaceutical company’s stock worth $53,018,000 after acquiring an additional 327,194 shares during the last quarter. Macquarie Group Ltd. lifted its stake in shares of Retrophin by 19.1% during the 3rd quarter. Macquarie Group Ltd. now owns 1,926,336 shares of the biopharmaceutical company’s stock worth $55,344,000 after acquiring an additional 308,718 shares during the last quarter. Handelsbanken Fonder AB lifted its stake in shares of Retrophin by 66.3% during the 4th quarter. Handelsbanken Fonder AB now owns 443,916 shares of the biopharmaceutical company’s stock worth $10,046,000 after acquiring an additional 176,916 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Retrophin by 17.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,087,025 shares of the biopharmaceutical company’s stock worth $31,229,000 after acquiring an additional 164,982 shares during the last quarter. Finally, First Trust Advisors LP lifted its stake in shares of Retrophin by 131.9% during the 3rd quarter. First Trust Advisors LP now owns 160,878 shares of the biopharmaceutical company’s stock worth $4,622,000 after acquiring an additional 91,513 shares during the last quarter.

Shares of NASDAQ:RTRX traded up $0.04 during trading on Monday, hitting $21.47. The company had a trading volume of 120,659 shares, compared to its average volume of 362,984. The firm has a market capitalization of $883.99 million, a price-to-earnings ratio of -14.31 and a beta of 1.38. Retrophin has a one year low of $19.77 and a one year high of $33.00. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.04 and a quick ratio of 4.99.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Further Reading: Trading Strategy Examples and Plans

Get a free copy of the Zacks research report on Retrophin (RTRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply